Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 6

Tolvaptan and its potential in the treatment of hyponatremia

Authors Dixon M, Lien H

Published 5 December 2008 Volume 2008:4(6) Pages 1149—1155

DOI https://doi.org/10.2147/TCRM.S3115

Review by Single-blind

Peer reviewer comments 3

Megan B Dixon, Y Howard Lien

Department of Medicine, University of Arizona, Arizona Kidney Disease and Hypertension Center, Tucson, Arizona, USA

Abstract: Tolvaptan is a selective arginine vasopressin (AVP) V2 receptor blocker used to induce free water diuresis in the treatment of euvolemic or hypervolemic hyponatremia. Currently the orally active medication is in the final stages prior to approval by the FDA for outpatient therapy. It appears to be safe and effective at promoting aquaresis and raising serum sodium levels in both short- and long-term studies. Tolvaptan is also effective for treatment of congestive heart failure (CHF) exacerbation, but whether there are long standing beneficial effects on CHF is still controversial. Prolonged use of tolvaptan leads to increased endogenous levels of AVP and perhaps over-stimulation of V1A receptors. Theoretically this activation could lead to increased afterload and cardiac myocyte fibrosis, causing progression of CHF. However, after 52 weeks of tolvaptan therapy there was no worsening of left ventricular dilatation. In addition, tolvaptan is metabolized by the CYP3A4 system; thus physicians should be aware of the potential for increased interactions with other medications. Tolvaptan is a breakthrough in the therapy of hyponatremia as it directly combats elevated AVP levels associated with the syndrome of inappropriate secretion of antidiuretic hormone, congestive heart failure, and cirrhosis of the liver.

Keywords: hyponatremia, arginine vasopressin, vasopressin receptors, syndrome of inappropriate antidiuretic hormone, congestive heart failure, liver cirrhosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

A 41-year-old man with polyarthritis and severe autonomic neuropathy

Matthew E Bourcier, Aaron I Vinik

Therapeutics and Clinical Risk Management 2008, 4:837-842

Published Date: 8 August 2008

Resveratrol in prevention and treatment of common clinical conditions of aging

M Andrea Markus, Brian J Morris

Clinical Interventions in Aging 2008, 3:331-339

Published Date: 6 June 2008

An “acquired” hemoglobin J variant in a sickle cell disease patient

Nawwar Swedan, Kathleen Nicol, Phylis Moder, Samir Kahwash

Therapeutics and Clinical Risk Management 2008, 4:649-652

Published Date: 6 June 2008

Treating psoriasis with adalimumab

Eihab A Alwawi, Stephanie L Mehlis, Kenneth B Gordon

Therapeutics and Clinical Risk Management 2008, 4:345-351

Published Date: 11 April 2008

Leuprorelin depot injection: patient considerations in the management of prostatic cancer

Zinelabidine Abouelfadel, E David Crawford

Therapeutics and Clinical Risk Management 2008, 4:513-526

Published Date: 11 April 2008

Raltegravir: first in class HIV integrase inhibitor

Zelalem Temesgen, Dawd S Siraj

Therapeutics and Clinical Risk Management 2008, 4:493-500

Published Date: 11 April 2008